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ABSTRACT Zika virus (ZIKV) is an emerging mosquito-borne flavivirus. Recent ZIKV
outbreaks have produced serious human disease, including neurodevelopmental
malformations (congenital Zika syndrome) and Guillain-Barré syndrome. These out-
comes were not associated with ZIKV infection prior to 2013, raising the possibility
that viral genetic changes could contribute to new clinical manifestations. All con-
temporary ZIKV isolates encode an N-linked glycosylation site in the envelope (E)
protein (N154), but this glycosylation site is absent in many historical ZIKV isolates.
Here, we investigated the role of E protein glycosylation in ZIKV pathogenesis using
two contemporary Asian-lineage strains (H/PF/2013 and PRVABC59) and the histori-
cal African-lineage strain (MR766). We found that glycosylated viruses were highly
pathogenic in Ifnar1/ mice. In contrast, nonglycosylated viruses were attenuated,
producing lower viral loads in the serum and brain when inoculated subcutaneously
but remaining neurovirulent when inoculated intracranially. These results suggest
that E glycosylation is advantageous in the periphery but not within the brain. Ac-
cordingly, we found that glycosylation facilitated infection of cells expressing the
lectins dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin
(DC-SIGN) or DC-SIGN-related (DC-SIGNR), suggesting that inefficient infection of
lectin-expressing leukocytes could contribute to the attenuation of nonglycosy-
lated ZIKV in mice.
IMPORTANCE It is unclear why the ability of Zika virus (ZIKV) to cause serious dis-
ease, including Guillain-Barré syndrome and birth defects, was not recognized until
recent outbreaks. One contributing factor could be genetic differences between con-
temporary ZIKV strains and historical ZIKV strains. All isolates from recent outbreaks
encode a viral envelope protein that is glycosylated, whereas many historical ZIKV
strains lack this glycosylation. We generated nonglycosylated ZIKV mutants from
contemporary and historical strains and evaluated their virulence in mice. We found
that nonglycosylated viruses were attenuated and produced lower viral loads in se-
rum and brains. Our studies suggest that envelope protein glycosylation contributes
to ZIKV pathogenesis, possibly by facilitating attachment to and infection of lectin-
expressing leukocytes.
KEYWORDS Zika virus, flavivirus, Ifnar1/ mouse, glycosylation, DC-SIGN, CD209,
DC-SIGNR, L-SIGN, CD209L
Zika virus (ZIKV) is an emerging flavivirus primarily transmitted by mosquitos. MostZIKV infections are asymptomatic, with approximately 20% resulting in self-limiting
illness, including maculopapular rash, fever, and/or conjunctivitis (1, 2). Historically,
ZIKV was not associated with significant human disease. However, recent ZIKV out-
breaks have featured new clinical manifestations. The 2013–2014 ZIKV outbreak in
French Polynesia was associated with an increase in Guillain-Barré syndrome, an
autoimmune neuropathy that can result in weakness, paralysis, and death (2–4). The
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subsequent detection of ZIKV in Brazil in 2015 and the rapid spread of ZIKV to many 
countries in the Americas (5–8) has revealed that ZIKV infection during pregnancy can 
cause a broad range of congenital malformations termed congenital Zika syndrome (2, 
9, 10).
ZIKV is grouped into two major phylogenetic lineages, African and Asian. All 
contemporary American strains belong to the Asian lineage, and genetic analyses 
support a model of a single introduction of ZIKV to Brazil from the South Pacific (7, 8, 
11). It is unknown why severe disease manifestations, such as congenital Zika syn-
drome, were revealed only during the most recent ZIKV outbreak, but nonexclusive 
explanations include (i) the ability of a large outbreak with good surveillance to reveal 
rare outcomes, (ii) different host genetic or immune status in Latin America compared 
to regions where ZIKV circulated previously, and (iii) genetic changes in ZIKV strains 
resulting in altered tropism and/or enhanced pathogenesis (12). Amino acid substitu-
tions that may contribute to the increased rate of transmission and/or pathogenicity 
have been identified by comparative genomic and phylogenetic analyses (13–15). 
Differences in nonstructural protein 1 (NS1) and premembrane protein (prM) have been 
associated experimentally with enhanced transmission or virulence of American strains 
(11, 16–18). These analyses also have revealed a difference in the N-linked glycosylation 
motif (N-X-S/T) at amino acid 154 of the ZIKV envelope (E) protein. Many African-lineage 
ZIKV isolates lack the glycosylation signal due to either a 4- to 6-amino-acid deletion or 
a change of T to I at position 156, whereas all Asian-lineage strains, including ones from 
recent outbreaks, contain an intact glycosylation signal (19, 20). This is significant 
because N-linked glycosylation on E is associated with enhanced mosquito transmis-
sion and/or increased vertebrate virulence of other flaviviruses, including West Nile 
virus (WNV), Japanese encephalitis virus (JEV), tick-borne encephalitis virus, and others 
(21–30).
In this study, we investigated the role of E glycosylation in ZIKV pathogenesis 
across Asian- and African-lineage ZIKV strains. We used site-directed mutagenesis to 
ablate the glycosylation motif with a single amino acid substitution (N154Q) in a 
previously described infectious clone of the Asian-lineage ZIKV strain H/PF/2013 (31). 
We generated a new infectious clone of another widely used Asian-lineage ZIKV strain, 
PRVABC59, and ablated the glycosylation motif with either an N154Q or a T156I 
substitution. Finally, we used our previously reported infectious clones derived from the 
prototype African-lineage ZIKV strain MR766 TVP 14270 with a 4-amino-acid deletion 
ablating the glycosylation site, as well as mutants with restoration of the glycosylation 
signal or the 4 amino acids restored with a T156I mutation ablating the glycosylation 
signal (31). We show that mutant viruses lacking the E glycosylation are avirulent in 
Ifnar1/ mice and are attenuated in overall replication in vivo. We also show that the 
lectins dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin 
(DC-SIGN, CD209) and DC-SIGN-related (DC-SIGNR, CD209L, L-SIGN) facilitate infection 
of glycosylated virus in cell culture. Our results indicate that N-linked glycosylation of 
the ZIKV E protein mediates infection and pathogenesis and suggest that the glycan 
may enhance infectivity via cell surface lectins.
RESULTS
N154Q mutation ablates E glycosylation. To evaluate the role of E glycosylation 
in ZIKV infection, we used site-directed mutagenesis to introduce a single amino acid 
substitution, N154Q, that ablates the glycosylation motif (N-X-S/T) in a previously 
described infectious clone of ZIKV strain H/PF/2013 (Fig. 1A) (31). Consensus sequenc-
ing of virus released from electroporated Vero cells confirmed the two engineered 
nucleotide changes (Fig. 1B). We compared the growth of the H/PF/2013 isolate, a 
wild-type (WT) clone, and the N154Q mutant in Vero cells and found equivalent 
replication kinetics (Fig. 1C). To verify the glycosylation status of the viral E protein, we 
immunoprecipitated lysates from infected Vero cells with monoclonal antibody (MAb) 
1M7. We digested the immunoprecipitates with peptide N-glycosidase F (PNGase F) to 
remove all N-linked carbohydrates. When probed by Western blotting with MAb 4G2,
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FIG 1 E glycosylation is not required for ZIKV replication. (A) ZIKV envelope protein, depicting the nucleotide and amino acid residues
of the glycosylation site, and N154Q mutation. (B) Sequence chromatograms of E protein glycosylation site of wild-type (WT) and
N154Q viruses. (C) Vero cells were infected at an MOI of 0.01 with ZIKV H/PF/2013 isolate, WT clone, or N154Q mutant. Viruses in
culture supernatants were titrated by focus-forming assay. Data shown are the mean values  standard errors of the means (SEM) of
9 samples from 3 independent experiments. (D and E) E proteins were immunoprecipitated with MAb 1M7 from lysates of Vero cells
infected with ZIKV H/PF/2013 isolate, WT clone, N154Q mutant, or DENV. (D) Lysates were treated with PNGase F, separated by
nonreducing SDS-PAGE, and probed with MAb 4G2. (E) Lysates were separated by nonreducing SDS-PAGE and probed with
biotinylated concanavalin A to detect glycans. FT, flow-through; IP, immunoprecipitate.
E protein from H/PF/2013 isolate virus and WT infectious clones exhibited a lower 
molecular weight after PNGase F treatment, indicating glycan cleavage (Fig. 1D). 
However, the size of the N154Q E protein was unaffected by PNGase F digestion, 
indicating that the mutant E protein was not glycosylated. Compared to that of ZIKV, 
dengue virus (DENV) E protein exhibited a greater size shift upon PNGase F digestion, 
as expected, because DENV E has two glycosylation sites (N67 and N153) (32). We 
further confirmed the glycosylation state of the viral E protein by lectin blotting, using 
biotinylated concanavalin A (ConA), a mannose/glucose binding lectin, to probe E 
protein immunoprecipitated from infected Vero cells. Consistent with the results from 
PNGase F digestion, the H/PF/2013 isolate and WT clone E proteins were detected by 
ConA, whereas the N154Q E protein was not (Fig. 1E).
ZIKV E N154Q is attenuated upon subcutaneous but not intracranial inocula-
tion. We next evaluated the virulence of the N154Q mutant in mice. ZIKV does not 
replicate efficiently in WT C57BL/6 mice because ZIKV NS5 protein does not antagonize 
mouse STAT2 (33, 34). Thus, mouse models of ZIKV pathogenesis typically employ mice 
lacking interferon alpha/beta (IFN-) signaling, such as through genetic loss of the 
IFN- receptor (Ifnar1/) (35, 36). To evaluate the role of E glycosylation in ZIKV 
pathogenesis, we infected 5- to 6-week-old Ifnar1/ mice with 1  103 focus-forming 
units (FFU) of WT or N154Q virus by a subcutaneous route in the footpad and evaluated 
weight loss and lethality (Fig. 2A and B). Mice infected with WT clone virus began losing 
weight at 4 days postinfection (dpi), and all mice succumbed by 7 dpi, consistent with 
previous studies with the H/PF/2013 isolate virus (35). In contrast, mice infected with



























































































Ifnar1-/- Intracranial Infection WT Intracranial Infection
FIG 2 ZIKV E N154Q is attenuated upon subcutaneous but not intracranial inoculation. Five- to six-week-old Ifnar1/ or wild-type (WT) mice were
inoculated with 1  103 FFU of ZIKV strain H/PF/2013 WT clone or N154Q mutant by a subcutaneous (A and B) or intracranial (C to E) route. Mice
were weighed daily, and weights are expressed as percentages of body weight prior to infection. Results shown are the mean values  SEM of
6 to 8 Ifnar1/ mice or 3 WT mice per virus from two or three independent experiments. Lethality was monitored for 14 days.
the N154Q virus lost weight from 5 to 7 dpi but recovered, and all mice survived. 
Studies with ZIKV and other flaviviruses have identified a role for E glycosylation in 
neuroinvasion (23, 24, 37), so we tested whether the N154Q mutant regained virulence 
if the blood-brain barrier was bypassed. We infected WT and Ifnar1/ mice with 
1  103 FFU of WT or N154Q virus by intracranial inoculation and found that both 
viruses caused equivalent weight loss and lethality (Fig. 2C to E). Six of 7 Ifnar1/ mice 
infected with the N154Q mutant died, while 1 mouse lost weight and recovered. WT 
mice lost weight from 4 to 6 dpi, but all mice recovered and all mice survived infection 
with both viruses. Overall, these results indicate that ZIKV N154Q remained neuroviru-
lent, even though this virus was attenuated via a subcutaneous inoculation route.
ZIKV E N154Q has impaired replication in vivo. Since the ZIKV N154Q virus was 
avirulent following subcutaneous inoculation but lethal upon intracranial inoculation, 
we tested whether E glycosylation mediated neuroinvasion, as well as invasion into 
other specialized tissue compartments, such as the eyes and testes, compared to 
peripheral tissues such as blood and the spleen. We infected 5-week-old Ifnar1/ mice 
with 1  103 FFU of WT or N154Q virus via subcutaneous footpad inoculation and 
measured viral loads in the serum at 2, 4, and 6 dpi (Fig. 3A) and viral loads in tissues 
at 6 dpi by reverse transcription-quantitative PCR (qRT-PCR) (Fig. 3B to E). Compared to 
the WT virus, ZIKV N154Q produced lower viral loads in the serum at all time points, as 








































































































































FIG 3 N154 glycosylation mediates ZIKV infection in mice. Five- to six-week-old Ifnar1/ mice were inoculated with 1  103 FFU of ZIKV strain
H/PF/2013 WT clone or N154Q mutant by a subcutaneous route in the footpad. (A) Blood was collected at 2, 4, and 6 days after infection, and
ZIKV RNA in serum was measured by qRT-PCR. (B to E) Mice were euthanized 6 days after infection and perfused, and tissues were harvested. ZIKV
RNA in tissue was measured by qRT-PCR. **, P  0.01; ***, P  0.001; ****, P  0.0001; ns, not significant (unpaired 2-tailed t test).
and testes were not affected by E glycosylation. These results indicate that ZIKV 
H/PF/2013 N154Q, lacking the E glycosylation, was attenuated and produced lower 
viremia, which could contribute to lower viral loads detected in some tissues.
Low levels of ZIKV detected in the brains of N154Q-infected mice could result from 
delayed or inefficient neuroinvasion by the nonglycosylated virus. Alternatively, the 
attenuated mutant could revert in the periphery, producing WT virus that infects the 
brain. To distinguish these possibilities, we extracted RNA from brains 6 days after 
footpad inoculation with ZIKV N154Q and evaluated viral E sequences by Sanger 
sequencing. Based on sequencing chromatograms, 7 of 10 brains contained a mixture 
of WT and N154Q virus, 1 brain contained predominantly WT virus, and 2 brains 
contained predominantly N154Q virus. To determine whether the N154Q mutant was 
stable in the periphery, we performed Sanger sequencing on RNA extracted from serum 
2 days after infection with ZIKV N154Q. We found that serum from 2 of 5 mice 
sequenced contained a mixture of WT and N154Q virus, while the N154Q mutation was 
maintained in 3 mice. We next sequenced virus from brains harvested 5 to 8 days after 
intracranial inoculation with ZIKV N154Q and found that the N154Q mutation was 
maintained in 6 of 6 mice. Altogether, these data suggest selection favoring glycosy-
lated virus in peripheral tissues but not within the brain of ZIKV-infected Ifnar1/ mice.
Asian- and African-lineage strains lacking the E glycosylation are attenuated. 
ZIKV strain H/PF/2013 was isolated from an outbreak in French Polynesia in 2013, which 
preceded the emergence of ZIKV in the Americas and only retrospectively was associ-
ated with cases of congenital Zika syndrome (38–41). Since other reports of a role for 
E glycosylation in mediating ZIKV virulence used an African-lineage strain (37) or a  
Cambodian strain from 2010 (42), we sought to determine if glycosylation mediated 
similar effects on virulence and tissue invasiveness in a contemporary ZIKV strain from 
Latin America. We generated a new infectious clone of another widely used contem-
porary Asian-lineage strain, PRVABC59 (Puerto Rico, 2015) (Fig. 4A) (43). Due to the high 
nucleotide identity between H/PF/2013 and PRVABC59 (99%), we were able to use 
the same restriction endonuclease sites to partition the viral genome across four 
plasmids, as previously described (31). Following digestion, ligation, in vitro transcrip-
tion, and electroporation into Vero cells, infectious virus was recovered. The virus was 
passaged once on Vero cells, and titers were determined by focus-forming assay (FFA). 
The open reading frame of the WT infectious clone was sequenced, and we confirmed 
that no new mutations were introduced compared to the reference genome sequence 
for this strain (accession number KU501215). We used site-directed mutagenesis to 
introduce a single amino acid substitution (N154Q) to ablate the glycosylation motif 
(N-X-S/T). We also made a second mutant virus with the glycosylation motif ablated by 
a T156I mutation, as this variant has been detected in ZIKV strains isolated from 
mosquitos in Africa in the 1970s and 1980s (20, 44). The region surrounding the
WT Clone N154Q T156I
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FIG 4 Generating an infectious clone of ZIKV PRVABC59 and nonglycosylated mutants. (A) An infectious clone of ZIKV strain PRVABC59 was
generated using a system that divides the viral genome into 4 fragments flanked by the indicated restriction endonuclease sites. Numbers above
fragments indicate nucleotide position in the viral genome. T7 promoter and a hepatitis delta virus (HDV) ribozyme sequences flank the genome.
(B) Sequence chromatograms of E protein glycosylation site of WT, N154Q, or T156I clone. (C) Vero cells were infected at an MOI of 0.01 with ZIKV
PRVABC59 isolate, WT clone, N154Q mutant, or T156I mutant. Viruses in culture supernatants were titrated by focus-forming assay. Data shown
are the mean values  SEM of 9 samples from 3 independent experiments. (D and E) E proteins were immunoprecipitated with MAb 1M7 from
lysates of Vero cells infected with ZIKV PRVABC59 isolate, WT clone, N154Q mutant, or T156I mutant. (D) Lysates were treated with PNGase F,
separated by nonreducing SDS-PAGE, and probed with MAb 4G2. (E) Lysates were separated by nonreducing SDS-PAGE and probed with
biotinylated lectin concanavalin A.
introduced mutation was sequenced (Fig. 4B). All four viruses replicated equivalently in 
Vero cells (Fig. 4C). We performed PNGase F digestion (Fig. 4D) and lectin blotting (Fig. 
4E) on immunoprecipitated E protein from Vero cells infected with PRVABC59 isolate, 
WT clone, N154Q mutant, and T156I mutant viruses to confirm the E glycosylation state. 
PNGaseF digestion produced a size shift for the PRVABC59 isolate and WT clone E 
proteins but not for the two mutants (Fig. 4D). Lectin blotting showed a band for the 
PRVABC59 isolate and the WT clone E proteins, but no band was detected for the two 
mutants lacking the E glycosylation (Fig. 4E). These results indicate that ZIKV PRVABC59 
isolate and WT clone E protein are glycosylated and that this glycosylation is ablated by 
either N154Q or T156I mutations.
We next tested the virulence of the PRVABC59 viruses in Ifnar1/ mice. We infected 
5- to 6-week-old mice with 1  103 FFU of PRVABC59 isolate, WT clone, N154Q, or T156I 
viruses via subcutaneous footpad inoculation and measured viral loads in the serum at 
2, 4, and 6 dpi (Fig. 5A) and tissues at 6 dpi by qRT-PCR (Fig. 5B to E). The WT clone 
produced viral loads similar to those of the isolate virus. However, both nonglycosy-





































































































































FIG 5 E glycosylation mediates ZIKV PRVABC59 infection in mice. Five- to six-week-old Ifnar1/ mice were inoculated with
1  103 FFU of ZIKV strain PRVABC59 isolate, WT clone, N154Q mutant, or T156I mutant by a subcutaneous route in the
footpad. (A) Blood was collected at 2, 4, and 6 days after infection, and ZIKV RNA levels in serum were measured by
qRT-PCR. (B to E) Mice were euthanized 6 days after infection and perfused, and tissues were harvested. ZIKV RNA in tissues
was measured by qRT-PCR. Data are combined from 2 independent experiments. *, P  0.05; ***, P  0.001; ****,
P  0.0001; ns, not significant (ANOVA).
serum, as well as in the brain and eyes, indicating that like strain H/PF/2013, ZIKV 
PRVABC59 infection is mediated by E protein glycosylation in vivo. Similar to the results 
for strain H/PF/2013, glycosylation did not impact ZIKV PRVABC59 viral loads in the 
spleen or testes. The observation that N154Q and T156I mutants produced very similar 
viral loads is consistent with a specific role for glycosylation in ZIKV infection, rather 
than an effect of the Asn residue itself. As we did for the experiments with ZIKV 
H/PF/2013, we used Sanger sequencing to evaluate viral E sequences from brains 
harvested 6 days after footpad infection with the ZIKV PRVABC59 N154Q or T156I 
mutant. In contrast to the results for the H/PF/2013 strain, we found that the mutations 
were maintained in all 11 brains evaluated (5 infections with the N154Q mutant and 6 
with the T156I mutant). These results could indicate that E glycosylation provides a 
selective advantage for ZIKV H/PF/2013 but not PRVABC59. Alternatively, E glycosyla-
tion may be advantageous for both strains, but our stock of H/PF/2013 N154Q virus 
could contain revertants at a level below the sensitivity of our Sanger sequencing assay, 
allowing for more rapid selection and amplification in vivo than for the PRVABC59 
viruses.
H/PF/2013 and PRVABC59 are both Asian-lineage ZIKV strains, closely related to ZIKV 
strains circulating in the Americas (15, 45). However, the prototype ZIKV strain, MR766, 
is an African-lineage strain isolated from a sentinel rhesus macaque in 1947 and 
subsequently maintained by extensive passage in suckling mouse brains (150 pas-
sages) (46). Likely due to this long history, several variants of MR766 have been used by 
different groups, and nonidentical sequences deposited in NCBI (47, 48). Among the 
many differences in reference sequences for ZIKV strains named “MR766” is the 
glycosylation signal at N154, with some sequences encoding an intact glycosylation





































































































































































FIG 6 E glycosylation mediates ZIKV MR766 infection in mice. (A and B). Seven- to 10-week-old Ifnar1/ mice were inoculated with 1  103 FFU of ZIKV strain
MR766 isolates containing the E glycan (gly) or lacking the E glycan (gly) by a subcutaneous route in the footpad. Mice were weighed daily, and weights
are expressed as percentages of body weight prior to infection and censored once one mouse in a group died. Results shown are the mean values  SEM of
14 to 16 Ifnar1/ mice per virus. Lethality was monitored for 21 days. (C to G) Five-week-old Ifnar1/ mice were inoculated with 1  103 FFU of ZIKV strain
MR766 gly clone, gly clone 4-amino-acid deletion (4AAΔ), or T156I clone by a subcutaneous route in the footpad. (C) Blood was collected at 2 and 4 days
after infection, and ZIKV RNA levels in serum were measured by qRT-PCR. (D to G) Mice were euthanized 4 days after infection and perfused, and tissues were
harvested. ZIKV RNA in tissues was measured by qRT-PCR. **, P  0.01; ***, P  0.001; ****, P  0.0001; ns, not significant (ANOVA).
signal (accession number HQ234498.1), some with a T-to-I point mutation that ablates 
the glycosylation signal (accession number LC002520.1), and others with a 4- to 
6-amino-acid deletion that ablates the glycosylation signal (accession numbers 
DQ859059.1, AY632535.2, and NC_012532.1). To determine whether different MR766 
variants exhibited similar levels of virulence in vivo, we compared two MR766 isolates 
obtained from the World Reference Center for Emerging Viruses and Arboviruses: TVP 
14270 (SM 150, 7 February 2011) and M4946 (SM 146, 14 October 1952). By Sanger 
sequencing, we determined that M4946 had an intact glycosylation signal (gly) at 
N154, whereas TVP 14270 had a 4-amino-acid deletion ablating this signal (gly). We 
infected 7- to 10-week-old Ifnar1/ mice with 1  103 FFU of MR766 isolate strains by 
subcutaneous footpad inoculation. Consistent with a role for E glycosylation in medi-
ating ZIKV virulence, mice infected with M4946 (gly) lost weight faster and exhibited 
100% lethality by 9 dpi, whereas only 20% of mice infected with TVP14270 (gly) 
succumbed (Fig. 6A and B). These results are consistent with our previous studies which 
used MR766 TVP14270 (gly) (35). We previously reported an infectious clone derived 
from MR766 TVP 14270 (gly), as well as mutants that restored the N154 glycosylation 
signal (gly) or restored the 4-amino-acid deletion but with the T156I mutation 
ablating the glycosylation signal (31). To compare the levels of virulence of these 
isogenic mutants, we infected 5-week-old Ifnar1/ mice with 1  103 FFU of MR766 
gly, gly, and T156I clone viruses via subcutaneous footpad inoculation and mea-
sured viral loads in serum at 2 and 4 dpi (Fig. 6C) and in tissues at 4 dpi (Fig. 6D to G). 
Tissues were harvested at 4 dpi, rather than 6 dpi, because mice succumbed to thegly 
virus by 5 dpi, consistent with reports of MR766gly being more pathogenic than
Asian-lineage strains (49) and MR766 gly being less pathogenic than H/PF/2013 (35). 
Similar to the results for ZIKV H/PF/2013 and PRVABC59, we observed lower viral loads 
at all time points in the serum and in the brain, but not in the testes or spleen, in mice 
infected with the gly and T156I viruses than in mice infected with thegly virus. In 
the eyes, we found significantly lower viral loads with the gly virus, but not the T156I 
virus, compared to thegly virus. Altogether, our data indicate that ZIKV variants 
lacking the E protein glycosylation, in both African- and Asian-lineage strains, are 
attenuated compared to viruses with E protein glycosylation.
Lectins DC-SIGN and DC-SIGNR mediate infection of glycosylated ZIKV. All 
nonglycosylated ZIKV variants that we tested (6 viruses from strains H/PF/2013, 
PRVABC59, and MR766) replicated equivalently to their glycosylated counterparts in 
Vero cells but produced significantly lower levels of viremia in Ifnar1/ mice. One 
possible explanation for the in vivo attenuation of nonglycosylated viruses could be 
lower infectivity due to an inability to bind to attachment factors. The lectins DC-SIGN 
and DC-SIGNR mediate attachment and entry of flaviviruses, including DENV (50–52), 
WNV (53–55), and JEV (30, 56). DC-SIGN is highly expressed in macrophages and 
dendritic cells, while DC-SIGNR is expressed on microvascular endothelial cells, espe-
cially in the liver sinusoids, lymph nodes, and placental villi (57). To test whether ZIKV 
E glycosylation facilitates lectin-mediated attachment and infectivity, we used Raji cells 
and Raji cells expressing DC-SIGN (Raji-DC-SIGN) or DC-SIGNR (Raji-DC-SIGNR) and 
measured infection by flow cytometry. We confirmed that DC-SIGN and DC-SIGNR were 
expressed on the surface of the appropriate cell type but not parental Raji cells (Fig. 7A). 
Cells were infected with ZIKV (strain PRVABC59) WT clone, N154Q mutant, T156I 
mutant, or UV-inactivated WT clone virus at a multiplicity of infection (MOI) of 5, and 
intracellular E protein was measured 24 h postinfection (hpi) by flow cytometry (Fig. 7B 
and C). No E protein signal was detected in cells infected with UV-inactivated virus, 
confirming that our assay measured viral infection and replication, not residual inoc-
ulum. In the absence of exogenous lectin expression, Raji cells were not efficiently 
infected with ZIKV. However, WT ZIKV, with glycosylated E protein, infected Raji cells 
expressing exogenous DC-SIGN and, to a greater extent, DC-SIGNR. Infection by non-
glycosylated ZIKV (N154Q or T156I) was not augmented by DC-SIGN expression. 
Unexpectedly, the N154Q mutant was able to infect DC-SIGNR-expressing cells (albeit 
to a lesser extent than WT virus), while DC-SIGNR did not augment infection by the 
T156I mutant. Altogether, these data suggest that E glycosylation facilitates ZIKV 
infection of lectin-expressing leukocytes, which could contribute to lower viremia 
produced by nonglycosylated ZIKV in vivo.
We also used flow cytometry to measure infection of two epithelial cell lines 
commonly used in ZIKV studies, Vero and A549. Both of these cell lines lack DC-SIGN 
expression (data not shown), suggesting that entry occurs via different attachment 
factors. Consistent with the equivalent replication we observed for nonglycosylated 
ZIKV viruses in Vero cells (Fig. 1C and Fig. 4C), N154Q and T156I mutants exhibited 
similar infection efficiencies in Vero cells (75% compared to 85% of the cell 
population for WT virus) (Fig. 8A and B). Compared to Vero cells, A549 cells were less 
permissive to all viruses, but infection was more dependent on E glycosylation 
(5% infection with N154Q and T156I viruses compared to 20% for WT virus) (Fig. 
8C and D). The effect of E glycosylation on A549 cell infection also was evident in 
multistep growth curves, which showed that PRVABC59 N154Q and T156I mutants 
were attenuated by 10- to 100-fold compared to the WT clone (Fig. 8E). Likewise, 
replication of the H/PF/2013 N154Q mutant was significantly attenuated in A549 
cells compared to that of the WT clone (Fig. 8F). These data suggest that E 
glycosylation mediates ZIKV infection in A549 cells but is dispensable in Vero cells.
Altogether, our results demonstrate that E glycosylation facilitates ZIKV infection in 
a tissue-specific manner, which may result from augmented infection of cells express-
ing certain cell-surface lectins.
DISCUSSION
The emergence of ZIKV in the Western Hemisphere has been associated with new
clinical manifestations, including Guillain-Barre syndrome and congenital Zika syn-
drome (2). Phylogenetic analyses of ZIKV isolates from past and recent outbreaks have
revealed amino acid differences between historic African-lineage strains and the con-
temporary Asian-lineage strains that are currently circulating in the Western Hemi-
sphere (13–15). Several of these amino acid differences have been implicated in
transmission, immune suppression, and enhanced disease. A single amino acid substi-
tution (A188V) in NS1 has been shown to enhance ZIKV antigenemia in mice and
infectivity of Aedes aegypti mosquitos (16) and also inhibits IFN- production in cell
culture (17). A single amino acid substitution in prM (S139N) has been shown to
increase ZIKV replication in human neural progenitor cells and may contribute to a
more severe microcephalic phenotype in mice (18), although others found that this
mutation is not essential for fetal pathology in a mouse transplacental transmission
model (58).





























































FIG 7 E glycosylation facilitates ZIKV infection of DC-SIGN- and DC-SIGNR-expressing cells. (A) Representative flow cytometry plots of Raji,
Raji-DC-SIGN, and Raji-DC-SIGNR cells stained for cell surface expression of DC-SIGN and DC-SIGNR. (B) Representative flow cytometry plots of Raji,
Raji-DC-SIGN, and DC-SIGNR cells infected at an MOI of 5 with ZIKV PRVABC59 WT, N154Q, T156I, or UV-inactivated WT virus. Cells were stained at
24 hpi with Alexa Fluor 488-conjugated ZIKV MAb 4G2 to detect intracellular E protein. Values indicate the proportions of cells staining positive. (C)
































































































FIG 8 E glycosylation facilitates ZIKV infection of A549 but not Vero cells. (A to D) Vero and A549 cells were infected at an MOI of 5 with ZIKV PRVABC59 WT,
N154Q, or T156I clones. Cells were stained at 24 hpi with Alexa Fluor 488-conjugated ZIKV MAb 4G2 to detect intracellular E protein. (A and C) Representative
flow cytometry plots of infected Vero or A549 cells. (B and D) Percentages of infected (E positive) Vero or A549 cells combined from 3 independent experiments
performed in triplicate. (E and F) A549 cells were infected at an MOI of 0.01 with ZIKV PRVABC59 WT clone, N154Q mutant, or T156I mutant or with ZIKV
H/PF/2013 WT clone or N154Q mutant. Viruses in culture supernatants were titrated by focus-forming assay. Data shown are the mean values  SEM of 9
samples from 3 independent experiments.
N154Q. In contrast, many historic African-lineage ZIKV strains lack this motif (20, 44), 
though limited sampling of African ZIKV strains precludes robust conclusions about 
how common nonglycosylated viruses are in nature. E glycosylation plays a role in 
attachment and infectivity for DENV (50), WNV (53, 55, 59), and JEV (56) and has been 
associated with enhanced mosquito transmission and/or increased virulence and neu-
roinvasion in vertebrates for other flaviviruses (21–30). We investigated the role of the 
ZIKV E glycosylation in tissue tropism and pathogenesis in an immunocompromised 
mouse model. Our results indicate that both Asian- and African-lineage ZIKV strains 
lacking E glycosylation sustained lower tissue viral loads than did WT virus. These 
results are consistent with other reports of a role for E glycosylation in mediating ZIKV 
virulence. Annamalai et al. showed that ZIKV strain MR766 lacking E glycosylation due 
to a 4-amino-acid deletion or an N154A substitution produced lower viral loads in 
serum and brains of A129 mice than did glycosylated virus (37). Similarly, Fontes-Garfias 
et al. showed that a Cambodian ZIKV strain lacking E glycosylation due to an N154Q
substitution resulted in decreased viral loads in serum of A129 mice compared to the 
WT glycosylated virus (42). Notably, even though we found that ZIKV lacking E
glycosylation resulted in lower viral loads than did glycosylated virus in the serum, eyes, 
and brains, we observed similar viral loads in the spleen and testes, consistent with a 
previous report that glycosylated and nonglycosylated ZIKV strain MR766 sustained
similar viral loads in the spleen and liver (37). Likewise, a nonglycosylated mutant of 
Tembusu virus produced equivalent viral loads in the spleens of infected ducks, despite
reduced viral loads in other tissues (26). Furthermore, our observation that the ZIKV 
H/PF/2013 N154Q mutation was maintained upon intracranial inoculation but selected 
against after subcutaneous inoculation suggests that glycosylation provides a selective 
advantage to ZIKV in peripheral tissues but not within the brain. Altogether, these 
observations suggest that E glycosylation facilitates infection of ZIKV, and perhaps 
other flaviviruses, in a tissue or cell type-specific manner.
E glycosylation likely facilitates attachment to and infection of lectin-expressing
cells, including CD14 monocyte cells that are targets of ZIKV in humans (60–63). 
DC-SIGN and DC-SIGNR are among several attachment factors described for flaviviruses,
such as DENV (50, 51, 64), JEV (30, 56), and WNV (53, 54, 59), as well as for ZIKV (65–67), 
though it is less clear which lectins or other attachment factors actually mediate ZIKV
infection in mice or humans (68–70). Though mice do not have clear DC-SIGN or 
DC-SIGNR orthologs, they have eight DC-SIGN homologs clustered within the same
genomic region (60). According to their glycan specificity, murine SIGNR1 and SIGNR3 
are the closest candidates to fulfill DC-SIGN function in mice, but their ability to 
facilitate flavivirus infection is unclear. Unexpectedly, we found that DC-SIGNR was able 
to augment infection by the N154Q mutant, even in the absence of E glycosylation, 
which was unlike the T156I mutant. The different infection efficiencies of the two 
nonglycosylated mutants on Raji-DC-SIGNR cells could result from less efficient matu-
ration of N154Q virions than of T156I virions; in this case, glycosylated prM on immature
N154Q virions may partially complement the loss of E glycosylation (67). Cleavage of
prM is required to produce mature infectious flavivirus virions because interactions 
between prM and E prevent the conformational changes required to drive pH-
dependent membrane fusion, but partially mature virions also can be infectious (71).
The cleaved portion of prM is glycosylated, and uncleaved prM on partially mature
virions can facilitate attachment and entry in a DC-SIGNR-dependent manner (54, 67). 
Alternatively, the difference in infection efficiencies in DC-SIGNR cells could indicate a 
specific role for Gln 154 or Thr 156 independent of glycosylation, perhaps through
modulation of the glycan loop and resulting effects on attachment and fusion (67, 72). 
Overall, our findings demonstrate a role for E glycosylation in ZIKV pathogenesis, 
possibly by facilitating attachment to and infection of lectin-expressing leukocytes.
MATERIALS AND METHODS
Cells and viruses. Vero and A549 cells were maintained in Dulbecco’s modified Eagle medium 
(DMEM) containing 10% heat-inactivated fetal bovine serum (FBS) and L-glutamine at 37°C with 5% CO2. 
Raji, Raji-DC-SIGN, and Raji-DC-SIGNR cells were obtained from Theodore Pierson (NIH) (54). Raji cells 
were maintained in RPMI 1640 medium supplemented with 10% FBS and penicillin-streptomycin. ZIKV 
strains H/PF/2013 and PRVABC59 were provided by the U.S. Centers for Disease Control and Prevention 
(41, 43). The ZIKV MR766 strains were obtained from the World Reference Center for Emerging Viruses 
and Arboviruses (46–48). The DENV-3 WHO reference strain (CH54389) was obtained from Aravinda de 
Silva (UNC) (73). Virus stocks were grown in Vero (African green monkey kidney epithelial) cells. Virus 
stocks were titrated on Vero cells by focus-forming assay (FFA) (74). For multistep growth analysis, cells 
were infected at an MOI of 0.01 and incubated at 37°C with 5% CO2. Samples of infected cell culture 
supernatant were collected at 4, 24, 48, and 72 hpi and stored at 80°C for virus titration. Virus 
quantification was performed by FFA on Vero cells. Duplicate serial 10-fold dilutions of virus in viral 
growth medium (DMEM containing 2% FBS and 20 mM HEPES) were applied to Vero cells in 96-well 
plates and incubated at 37°C with 5% CO2 for 1 h. Cells were then overlaid with 1% methylcellulose in 
minimum essential medium Eagle (MEM). Infected cell foci were detected 42 to 46 hpi. Following fixation 
with 2% paraformaldehyde for 1 h at room temperature, plates were incubated with 500 ng/ml of 
flavivirus cross-reactive mouse MAb E60 (75) for 2 h at room temperature or overnight at 4°C. After 
incubation at room temperate for 2 h with a 1:5,000 dilution of horseradish peroxidase (HRP)-conjugated 
goat anti-mouse IgG (Sigma), foci were detected by the addition of TrueBlue substrate (KPL). Foci were 
quantified with a CTL Immunospot instrument. To prepare UV-inactivated virus, 20 ml of PRVABC59 WT
clone virus (1  105 FFU/ml) was placed in a petri dish and exposed to UV light at 0.9 J/cm2 for 10 min 
in an HL-2000 HybriLinker (UVP Laboratory Products); inactivation was confirmed by FFA.
ZIKV infectious clone design and mutagenesis. We used a quadripartite unidirectional molecular 
clone strategy, as previously described (31), to generate a new infectious clone of ZIKV strain PRVABC59. 
Due to the high sequence similarity between H/PF/2013 and PRVABC59, we were able to use the same 
naturally occurring class IIG nonpalindromic restriction endonuclease sites within the full-length genome 
as previously described for ZIKV strain H/PF/2013 (31). NotI and EcoRV restriction endonuclease sites, 
followed by a T7 promoter sequence for in vitro transcription, were added to the immediate 5= end of 
the genome. A hepatitis delta virus (HDV) ribozyme sequence, to generate an intact 3= untranslated 
region (UTR), followed by an SmaI restriction endonuclease site, was added directly after the last 
nucleotide of the genome. The four subgenomic fragments were synthesized into the pUC-57 vector 
(BioBasic) and amplified in One Shot TOP10 chemically competent Escherichia coli cells (Thermo) grown 
on LB plates with carbenicillin at 37°C for 16 h. Individual colonies were picked, grown in selective LB, 
purified (Qiagen mini-spin kit), and sequenced. The resulting purified plasmids were digested, ligated, in 
vitro transcribed, and electroporated into Vero cells as previously described (76). Supernatants from 
electroporated Vero cells were harvested after 6 to 7 days and passaged once on Vero cells to generate 
virus stocks. Virus stocks were titrated by FFA on Vero cells. Site-directed mutagenesis was used to 
introduce a single amino acid substitution (N154Q or T156I) in the envelope protein to ablate the 
glycosylation motif. Restriction enzymes and the Phusion high-fidelity PCR kit were obtained from New 
England BioLabs. The SuperScript III first-strand synthesis kit was obtained from Invitrogen. Oligonucle-
otide primers and probes for DNA amplification, qRT-PCR, and sequencing were obtained from Sigma 
and IDT. The mMachine T7 ultra transcription kit was obtained from Ambion.
Glycosylation assays. MAbs E60, 1M7, and 4G2 all recognize the conserved flavivirus fusion loop and 
were produced by the UNC Protein Expression and Purification Core Facility (75, 77, 78). E protein was 
immunoprecipitated from infected Vero cell lysates using MAb 1M7 (1 g) and magnetic protein A/G 
beads (Pierce). Immunoprecipitated E protein was digested with peptide N-glycosidase F (PNGaseF; New 
England BioLabs) according to the manufacturer’s protocol with a minor modification. Instead of 
denaturation in the provided glycoprotein denaturation buffer containing dithiothreitol, immunopre-
cipitates were denatured in 0.5% SDS, because the epitope recognized by MAb 4G2 is reduction sensitive 
(79). PNGaseF digestions were separated by SDS-PAGE (7.5% precast polyacrylamide gels; Bio-Rad) under 
nonreducing conditions and analyzed by Western or lectin blotting. Proteins were transferred to a 
nitrocellulose membrane using a Trans-Blot Turbo transfer system (Bio-Rad). In Western blots, E protein 
was detected using MAb 4G2 as a primary antibody and HRP-conjugated goat anti-mouse IgG as a 
secondary antibody. For lectin blots, glycosylated E was detected with the biotinylated lectin conca-
navalin A (ConA; Vector Laboratories), followed by HRP-conjugated streptavidin. Pierce ECL Western 
blotting substrate was used to detect HRP (Thermo). Western and lectin blots were imaged on a 
ChemiDoc XRS system (Bio-Rad).
Mouse experiments. Animal husbandry and experiments were performed under the approval of the 
University of North Carolina at Chapel Hill Institutional Animal Care and Use Committee. Five- to 
6-week-old or 7- to 10-week-old male and female wild-type or Ifnar1/ mice on a C57BL/6 background 
were used. Mice were inoculated with 1  103 FFU of ZIKV in a volume of 50 l subcutaneously (footpad) 
or 25 l intracranially. Survival and weight loss were monitored for 14 or 21 days. Animals that lost 30%
of their starting weight or that became moribund were euthanized.
Measurement of viral loads. ZIKV-infected mice were sacrificed at 4 or 6 dpi and perfused with 
20 ml of phosphate-buffered saline (PBS). Spleen, kidney, testes, brain, and eyes were harvested and 
homogenized with zirconia beads (BioSpec) in a MagNA Lyser instrument (Roche Life Science) in 500 l 
(eyes) or 1 ml (all other tissues) of buffer RLT (Qiagen). Blood was collected at 2 and 4 dpi by 
submandibular bleeds with a 5-mm Goldenrod lancet and by cardiac puncture at 6 dpi. Blood was 
collected in serum separator tubes (BD), and serum was separated by centrifugation at 8,000 rpm for 
5 min. Tissues and serum from infected animals were stored at 80°C until RNA isolation. RNA was 
extracted with the RNeasy minikit (tissues) or viral RNA minikit (serum) (Qiagen). ZIKV RNA levels were 
determined by TaqMan one-step qRT-PCR on a CFX96 Touch real-time PCR detection system (Bio-Rad) 
using standard cycling conditions. Viral burdens are expressed on a Log10 scale as either viral RNA 
equivalents per ml after comparison with a standard curve produced using serial 10-fold dilutions of RNA 
extracted from a ZIKV stock or genome copies per ml after comparison with a standard curve produced 
using serial 100-fold dilutions of ZIKV A plasmid. The following previously published primer set was used 
to detect ZIKV H/PF/2013 and PRVABC59 RNA: forward, CCGCTGCCCAACACAAG; reverse, CCACTAACGT 
TCTTTTGCAGACAT; and probe, 56-FAM/AGCCTACCT/ZEN/TGACAAGCAATCAGACACTCAA/3IABkFQ (Inte-
grated DNA Technologies) (80). ZIKV MR766 RNA was detected using the following primers: forward, 
GGGCGTGTCATATTCCTTGT; reverse, TCCATCTGTCCCTGCATACT; and probe, 56-FAM/AGCCTACCT/ZEN/
TGACAAGCAATCAGACACTCAA/3IABkFQ (Integrated DNA Technologies).
Flow cytometry. Cells (2  104) were infected with ZIKV at an MOI of 5 for 1 h at 37°C in RPMI 1640 
or DMEM supplemented with 2% FBS. The cells were subsequently washed with fluorescence-activated 
cell sorting (FACS) buffer (PBS with 1% FBS) to remove excess virus and incubated at 37°C for 24 h. 
Following incubation, cells were washed with FACS buffer and fixed by adding 100 l of 1% parafor-
maldehyde (PFA) and incubating at 4°C for 10 min. Cells were subsequently washed with permeabiliza-
tion buffer (PBS with 0.1% bovine serum albumin [BSA] and 0.1% saponin). The permeabilized cells were 
stained for ZIKV E protein using MAb 4G2 conjugated to Alexa Fluor 488, diluted 1:200, for 30 min at 4°C. 
For extracellular staining, cell surface DC-SIGN and DC-SIGNR were stained using MAb 9E9A8 for DC-SIGN 
(BioLegend) and MAB162 for DC-SIGNR (R&D Systems) at 4°C for 30 min. After washing with FACS buffer,
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cells were fixed and permeabilized as described above. The permeabilized cells were stained with 
secondary anti-mouse IgG–peridinin chlorophyll protein (PerCP), diluted 1:100. The stained cells were 
subsequently washed with FACS buffer and analyzed using a Guava EasyCyte HT flow cytometer 
(Millipore).
Data analysis. All data were analyzed with GraphPad Prism software. Flow cytometry data were 
analyzed with FlowJo version 10 software. Kaplan-Meier survival curves were analyzed by the log-rank 
test, and weight losses were compared using two-way analysis of variance (ANOVA). For viral burden 
analysis, the log-transformed titers were analyzed by ANOVA or 2-tailed t test. P values of 0.05 indicated 
statistically significant differences.
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